4basebio Plc Share News (4BB)

4basebio to provide synthetic DNA to tier-one pharma firm

(Sharecast News) - 4basebio confirmed the provision of its synthetic DNA to an unnamed tier-one pharmaceutical company on Wednesday.

IN BRIEF: 4basebio to supply synthetic DNA for mRNA vaccine program

4basebio PLC - Cambridge, England-based life sciences company and manufacturer of synthetic DNA products - Announces the supply of its HQ synthetic DNA to an unnamed "Tier 1 pharma company". Says the client will use the synthetic DNA in late preclinical studies for an mRNA vaccine program. Financial details of the contract were not provided by 4basebio.

4basebio client gets approval to start trial in Australia

(Sharecast News) - Synthetic DNA product developer 4basebio announced on Thursday that its client, Helix Nanotechnologies, has achieved a significant milestone with the receipt of HREC approval in Australia.

4basebio updates markets on "key milestone" with client

(Alliance News) - 4basebio PLC on Thursday noted a "key milestone" with its client, which is progressing into a phase one clinical trial.

TRADING UPDATES: Alpha Real Trust says in "robust" financial shape

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

IN BRIEF: 4basebio wins DNA supply contract to support RNA therapies

4basebio PLC - Cambridge, England-based life-science tech company with proprietary technologies in the field of DNA synthesis - Announces success in tender process to supply research and GMP-grade synthetic DNA for the development of RNA therapeutics and vaccines at the CPI's RNA Centre of Excellence. The CPI is a UK government-supported organisation which offers development and scale-up services to companies. The Centre for Excellence is the name for its Darlington manufacturing facility.

4basebio inks significant DNA supply contract

(Sharecast News) - 4basebio announced a significant contract through a competitive tender process on Friday, to provide research and GMP-grade synthetic DNA for the advancement of RNA therapeutics and vaccines at CPI's RNA Centre of Excellence.

IN BRIEF: 4basebio interim loss widens as research costs increase

4basebio PLC - Heidelberg, Germany-based life sciences company - Pretax loss in the six months to June 30 widens to GBP3.9 million from GBP2.7 million a year prior. Revenue grows 57% to GBP238,000 from GBP152,000. Research and non-captialised development expenses however increase 56% to GBP1.6 million from GBP1.0 million. Administrative expenses increase 23% to GBP1.6 million from GBP1.3 million, as sales and marketing expenses increase to GBP248,000 from GBP97,000. Looking ahead, expects to secure new clients in the second half of 2023.

First-half losses narrow for 4basebio

(Sharecast News) - Biotechnology company 4basebio reported revenues from its DNA and Hermes products surpassing £0.2m in its first half on Thursday.

4basebio inks supply deal with Italy's Neomatrix

(Sharecast News) - Synthetic DNA biotechnology specialist 4basebio announced a product supply agreement with Neomatrix on Thursday, which it described as an Italian biotech focussed on personalised cancer immunotherapies.

TRADING UPDATES: abrdn Property's NAV rises; Foresight VCT's falls

(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued last week and not separately reported by Alliance News:

IN BRIEF: 4basebio and universities team up against Neurofibromatosis

4basebio PLC - Heidelberg, Germany-based life sciences company - Teams up with the University of Alabama and England-based Teesside University for a research project on Neurofibromatosis type 1, or NF1. The two universities have received USD1 million from US-based Gilbert Family Foundation for a three-year research programme. It aims to "life-changing gene therapy with applicability to all NF1 patients," 4basebio says. The firm will produce a non-viral vector for the universities, it adds.

4basebio enters neurofibromatosis collaboration with two universities

(Sharecast News) - Life sciences company 4basebio announced a collaboration with the University of Alabama (UA) and Teesside University (TU) on Friday, in a research project aimed at developing an effective treatment for neurofibromatosis type-1 (NF1).

UK shareholder meetings calendar - next 7 days

Losses to continue as 4basebio focuses on commercialisation

(Sharecast News) - Specialist DNA-focussed life sciences company 4basebio reported revenue of £0.34m in its final results on Monday, down from £0.46m year-on-year.